Larry Biegelsen
Stock Analyst at Wells Fargo
(3.73)
# 763
Out of 4,918 analysts
323
Total ratings
53.02%
Success rate
6.28%
Average return
Main Sectors:
Stocks Rated by Larry Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYK Stryker | Maintains: Overweight | $435 → $445 | $379.94 | +17.12% | 16 | Aug 1, 2025 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $6 → $3 | $1.70 | +76.99% | 7 | Aug 1, 2025 | |
| BAX Baxter International | Maintains: Equal-Weight | $33 → $24 | $21.56 | +11.34% | 17 | Aug 1, 2025 | |
| GKOS Glaukos | Maintains: Equal-Weight | $86 → $92 | $84.00 | +9.52% | 15 | Jul 31, 2025 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $12 → $15 | $13.27 | +13.04% | 7 | Jul 31, 2025 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $108 → $100 | $84.41 | +18.47% | 11 | Jul 31, 2025 | |
| PEN Penumbra | Maintains: Overweight | $315 → $290 | $243.05 | +19.32% | 19 | Jul 30, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $80 → $84 | $78.22 | +7.39% | 16 | Jul 25, 2025 | |
| NVCR NovoCure | Downgrades: Equal-Weight | $40 → $15 | $11.14 | +30.16% | 18 | Jul 25, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $118 → $124 | $105.23 | +17.84% | 14 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $559 → $599 | $476.73 | +25.65% | 20 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $27 | $15.76 | +71.32% | 2 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $9 | $7.65 | +17.65% | 14 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $118 → $93 | $69.81 | +33.22% | 17 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.29 → $0.68 | $1.02 | -33.33% | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $113 → $98 | $89.72 | +9.23% | 10 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $195 → $174 | $124.33 | +39.95% | 12 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $137 | $114.81 | +19.33% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $103 → $89 | $69.33 | +28.37% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $20 | $15.45 | +29.45% | 9 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $8.49 | +100.35% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $166 → $152 | $165.35 | -8.07% | 13 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $94 | $79.67 | +17.99% | 9 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $106 → $98 | $88.83 | +10.32% | 17 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $94 → $105 | $86.52 | +21.37% | 8 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $49 | $11.95 | +310.04% | 2 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $136 | $126.91 | +7.16% | 21 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $70 | $52.02 | +34.56% | 7 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $270 | $174.86 | +54.41% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $70.10 | - | 2 | Nov 2, 2017 |
Stryker
Aug 1, 2025
Maintains: Overweight
Price Target: $435 → $445
Current: $379.94
Upside: +17.12%
Pulmonx
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $6 → $3
Current: $1.70
Upside: +76.99%
Baxter International
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $33 → $24
Current: $21.56
Upside: +11.34%
Glaukos
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $86 → $92
Current: $84.00
Upside: +9.52%
Bausch + Lomb
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $13.27
Upside: +13.04%
Merit Medical Systems
Jul 31, 2025
Maintains: Overweight
Price Target: $108 → $100
Current: $84.41
Upside: +18.47%
Penumbra
Jul 30, 2025
Maintains: Overweight
Price Target: $315 → $290
Current: $243.05
Upside: +19.32%
Edwards Lifesciences
Jul 25, 2025
Maintains: Overweight
Price Target: $80 → $84
Current: $78.22
Upside: +7.39%
NovoCure
Jul 25, 2025
Downgrades: Equal-Weight
Price Target: $40 → $15
Current: $11.14
Upside: +30.16%
Boston Scientific
Jul 24, 2025
Maintains: Overweight
Price Target: $118 → $124
Current: $105.23
Upside: +17.84%
Jul 23, 2025
Maintains: Overweight
Price Target: $559 → $599
Current: $476.73
Upside: +25.65%
Jul 17, 2025
Maintains: Overweight
Price Target: $28 → $27
Current: $15.76
Upside: +71.32%
Jul 9, 2025
Downgrades: Equal-Weight
Price Target: $25 → $9
Current: $7.65
Upside: +17.65%
May 30, 2025
Maintains: Overweight
Price Target: $118 → $93
Current: $69.81
Upside: +33.22%
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.29 → $0.68
Current: $1.02
Upside: -33.33%
May 6, 2025
Maintains: Equal-Weight
Price Target: $113 → $98
Current: $89.72
Upside: +9.23%
May 6, 2025
Maintains: Equal-Weight
Price Target: $195 → $174
Current: $124.33
Upside: +39.95%
May 2, 2025
Maintains: Equal-Weight
Price Target: $146 → $137
Current: $114.81
Upside: +19.33%
May 1, 2025
Maintains: Overweight
Price Target: $103 → $89
Current: $69.33
Upside: +28.37%
May 1, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $15.45
Upside: +29.45%
Jan 30, 2025
Maintains: Overweight
Price Target: $13 → $17
Current: $8.49
Upside: +100.35%
Jan 23, 2025
Maintains: Equal-Weight
Price Target: $166 → $152
Current: $165.35
Upside: -8.07%
Dec 11, 2024
Maintains: Overweight
Price Target: $90 → $94
Current: $79.67
Upside: +17.99%
Nov 20, 2024
Maintains: Overweight
Price Target: $106 → $98
Current: $88.83
Upside: +10.32%
Aug 22, 2024
Maintains: Overweight
Price Target: $94 → $105
Current: $86.52
Upside: +21.37%
Dec 5, 2023
Upgrades: Overweight
Price Target: $40 → $49
Current: $11.95
Upside: +310.04%
Apr 5, 2023
Maintains: Overweight
Price Target: $140 → $136
Current: $126.91
Upside: +7.16%
May 11, 2022
Maintains: Overweight
Price Target: $80 → $70
Current: $52.02
Upside: +34.56%
Apr 8, 2020
Maintains: Overweight
Price Target: $279 → $270
Current: $174.86
Upside: +54.41%
Nov 2, 2017
Upgrades: Outperform
Price Target: n/a
Current: $70.10
Upside: -